Filgrastim biosimilar - Ratiopharm/Teva

Drug Profile

Filgrastim biosimilar - Ratiopharm/Teva

Alternative Names: Biograstim (Teva); Filgrastim BS Inj.; Filgrastim NK; Granix; Leucocyte growth factor - Teva; Leukocyte growth factor - Teva; Neutroval™; Ratiograstim; Short-acting G-CSF - Teva; Short-acting Granulocyte Colony Stimulating Factor - Teva; tbo-filgrastim; Tevagrastim; XM-02; XM02-filgrastim

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ratiopharm; SICOR Biotech UAB
  • Developer Nippon Kayaku; Ratiopharm; SICOR Biotech UAB; Teva Pharmaceutical Industries; Teva Pharmaceuticals Europe; Teva-KOWA-Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 19 Jan 2017 Teva Pharmaceutical Industries plans the phase III GRANIX trial in Healthy volunteers (SC) (NCT03029000)
  • 01 May 2015 Teva Pharmaceuticals initiates enrolment in a phase II trial (In infants, In children, In adolescents) for Neutropenia in Bulgaria (NCT02190721)
  • 01 May 2015 Teva Pharmaceuticals initiates a phase II trial (in infants, in children, in adolescents) for Neutropenia in USA, Hungary, Poland, Russia and Ukraine (NCT02190721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top